|
HY-148335-50mg
|
MedChemexpress LLC
|
IRG1-IN-1 [CAS 2407652-42-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-148335-1mL
|
MedChemexpress LLC
|
IRG1-IN-1 [CAS 2407652-42-8] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-P0122-1mg
|
MedChemexpress LLC
|
iRGD peptide [CAS 1392278-76-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P0122-10mg
|
MedChemexpress LLC
|
iRGD peptide [CAS 1392278-76-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P0122-5mg
|
MedChemexpress LLC
|
iRGD peptide [CAS 1392278-76-0]
|
|
Cancer-programmed cell death
|
|
|
HY-P0122B-1mg
|
MedChemexpress LLC
|
iRGD peptide 1 (TFA)
|
|
Cancer-programmed cell death
|
|
|
HY-P0122B-10mg
|
MedChemexpress LLC
|
iRGD peptide 1 (TFA)
|
|
Cancer-programmed cell death
|
|
|
HY-P0122B-5mg
|
MedChemexpress LLC
|
iRGD peptide 1 (TFA)
|
|
Cancer-programmed cell death
|
|
|
HY-N3011-1mg
|
MedChemexpress LLC
|
Iridin [CAS 491-74-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-N3011-10mg
|
MedChemexpress LLC
|
Iridin [CAS 491-74-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-N3011-5mg
|
MedChemexpress LLC
|
Iridin [CAS 491-74-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-N4010-1mg
|
MedChemexpress LLC
|
Iriflophenone [CAS 52591-10-3]
|
|
Cancer-programmed cell death
|
|
|
HY-N4010-10mg
|
MedChemexpress LLC
|
Iriflophenone [CAS 52591-10-3]
|
|
Cancer-programmed cell death
|
|
|
HY-N4010-5mg
|
MedChemexpress LLC
|
Iriflophenone [CAS 52591-10-3]
|
|
Cancer-programmed cell death
|
|
|
HY-N4010-1mL
|
MedChemexpress LLC
|
Iriflophenone [CAS 52591-10-3] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-N4008-1mg
|
MedChemexpress LLC
|
Iriflophenone 3-C-glucoside [CAS 104669-02-5]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-N4008-10mg
|
MedChemexpress LLC
|
Iriflophenone 3-C-glucoside [CAS 104669-02-5]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-N4008-5mg
|
MedChemexpress LLC
|
Iriflophenone 3-C-glucoside [CAS 104669-02-5]
|
|
Metabolism-protein/nucleotide metabolism
|
|
|
HY-N2587-10mg
|
MedChemexpress LLC
|
Irigenin [CAS 548-76-5]
|
|
Cancer-programmed cell death
|
|
|
HY-N2587-20mg
|
MedChemexpress LLC
|
Irigenin [CAS 548-76-5]
|
|
Cancer-programmed cell death
|
|
|
HY-N2587-5mg
|
MedChemexpress LLC
|
Irigenin [CAS 548-76-5]
|
|
Cancer-programmed cell death
|
|
|
HY-N2587-1mL
|
MedChemexpress LLC
|
Irigenin [CAS 548-76-5] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-16568-100mg
|
MedChemexpress LLC
|
Irinotecan (hydrochloride trihydrate) [CAS 136572-09-3]
|
|
Cancer-programmed cell death
|
|
|
HY-16568-200mg
|
MedChemexpress LLC
|
Irinotecan (hydrochloride trihydrate) [CAS 136572-09-3]
|
|
Cancer-programmed cell death
|
|
|
HY-16568-50mg
|
MedChemexpress LLC
|
Irinotecan (hydrochloride trihydrate) [CAS 136572-09-3]
|
|
Cancer-programmed cell death
|
|
